Denali Therapeutics (DNLI) Net Equity Issued and Repurchased (2017 - 2026)

Denali Therapeutics' (DNLI) quarterly Net Equity Issued and Repurchased came in at $12.4 million in Q1 2026, up 102.48% on a QoQ basis from -$499.3 million in Q4 2024.

Denali Therapeutics (DNLI) Net Equity Issued and Repurchased (2017 - 2026) Analysis & Trends

Denali Therapeutics (DNLI) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $12.4 million in Q1 2026.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $12.4 million in Q1 2026; TTM through Mar 2026 was $12.4 million, a 102.48% increase from a year earlier, with the FY2022 full-year figure at $296.2 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased for Q1 2026 stood at $12.4 million, up from -$499.3 million in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for DNLI reached as high as $499.3 million in Q1 2024 and fell as low as -$499.3 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Denali Therapeutics 4.37 Bn 4.37 Bn - 12.37 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 12.37 Mn
Mar 31, 2026 12.37 Mn
Dec 31, 2024 -499.25 Mn
Dec 31, 2024 -499.25 Mn
Mar 31, 2024 499.25 Mn
Mar 31, 2024 499.25 Mn
Mar 31, 2020 193.95 Mn
Mar 31, 2020 193.95 Mn
Dec 31, 2018 -94.41 Mn
Dec 31, 2018 -94.41 Mn
Mar 31, 2018 94.41 Mn
Mar 31, 2018 94.41 Mn
Dec 31, 2017 29.97 Mn
Dec 31, 2017 29.97 Mn